Syncona Limited Kemal Malik Appointed as Non-Executive Director (8872P)
15 Giugno 2020 - 08:00AM
UK Regulatory
TIDMSYNC
RNS Number : 8872P
Syncona Limited
15 June 2020
Syncona Limited
Kemal Malik Appointed as Non-Executive Director
15 June 2020
Syncona Ltd, a leading healthcare company focused on founding,
building and funding a portfolio of global leaders in life
sciences, announces the appointment of Dr Kemal Malik as a
Non-Executive Director with immediate effect. Kemal has 30 years of
experience in global pharmaceutical research and development and
has been responsible for bringing many innovative medicines to
commercialisation.
Kemal has spent much of his recent career at Bayer where, for
the last six years, he served on the Board of Management leading
innovation across the group. He was also responsible for Bayer
LEAPS during this time, an organisational unit for strategic
venturing in areas of disruptive innovation (cell and gene
therapy). For the ten years prior to this, Kemal was Head of Global
Development and Chief Medical Officer at Bayer Healthcare. His
early career began with roles in medical affairs, clinical
development and new product commercialisation at Bristol-Myers
Squibb.
Kemal qualified in medicine at Charing Cross and Westminster
Medical School (Imperial College) and is a Member of the Royal
College of Physicians. He is also a Non-Executive Director at
Acceleron Pharma, Inc., a Boston based biopharmaceutical company,
where he sits on the Nomination and Governance and Compensation
committees.
Melanie Gee, Chair of Syncona Limited, said: "Kemal brings a
wealth of experience in life science innovation and drug
development to our Board. Developing commercially-viable medicines
that will reach patients is a core pillar of our strategy and his
expertise will be highly important as we steer the Company towards
future growth and success."
Kemal Malik said: "I look forward to joining Syncona's
impressive Board and working with the world-class individuals in
its successful investment team. I am particularly excited to apply
my experience in commercialising medicines to support the
development of the potentially life-changing therapies within the
Syncona portfolio."
No further details are required to be disclosed under LR
9.6.13.
[ENDS]
Enquiries
Syncona Ltd
Siobhan Weaver / Annabel Clay
Tel : +44 (0) 20 3981 7940
FTI Consulting
Ben Atwell / Natalie Garland-Collins / Tim Stamper
Tel: +44 (0) 20 3727 1000
About Syncona
Syncona is a leading FTSE250 healthcare company focused on
founding, building and funding a portfolio of global leaders in
life science. Our vision is to build a sustainable, diverse
portfolio of 15 - 20 companies focused on delivering
transformational treatments to patients in truly innovative areas
of healthcare, through which we are seeking to deliver strong
risk-adjusted returns for shareholders.
We seek to partner with the best, brightest and most ambitious
minds in science to build globally competitive businesses. We take
a long-term view, underpinned by a strategic capital base which
provides us with control and flexibility over the management of our
portfolio. We focus on delivering dramatic efficacy for patients in
areas of high unmet need.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOAKKQBKOBKDDAD
(END) Dow Jones Newswires
June 15, 2020 02:00 ET (06:00 GMT)
Grafico Azioni Syncona (LSE:SYNC)
Storico
Da Feb 2024 a Mar 2024
Grafico Azioni Syncona (LSE:SYNC)
Storico
Da Mar 2023 a Mar 2024